US · COSM · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Cosmos Health Inc. (COSM) intrinsic value and stock valuation
$2.81as of 2026-11-21 · Mkt cap 11.69M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Cosmos Health Inc. DCF and intrinsic value
InvestorsCraft values COSM with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from COSM’s statements →
Cosmos Health Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- SCYNEXIS, Inc. (SCYX) $2.38
- Passage Bio, Inc. (PASG) $3.92
- Lisata Therapeutics, Inc. (LSTA) $0.90
- Femasys Inc. (FEMY) $1.24
- NuCana plc (NCNA) $0.75
- NEXGEL, Inc. (NXGL) $3.12
- MetaVia Inc. (MTVA) $1.01
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $65.3M | $54.4M | $53.4M | $50.4M | $56.2M |
| Operating income | -$-16.54M | -$-15.54M | -$-21.83M | -$-7.47M | -$-4.53M |
| Net income | -$-19.14M | -$-16.18M | -$-18.54M | -$-13.83M | -$-7.96M |
| EPSd | -$-631.89K | -$-844.91K | -$-1.55M | -$-7.17M | -$-12.06M |
| Operating cash flow | -$-8.45M | -$-7.72M | -$-15.64M | -$-14.87M | -$-7.1M |
| Capital expenditure | -$-60K | -$-420K | -$-9.17M | -$-380K | -$-890K |
| Free cash flow | -$-8.5M | -$-8.14M | -$-24.8M | -$-15.25M | -$-7.99M |
| Total assets | $65.5M | $54.3M | $66M | $68M | $49.4M |
| Total debt | $20M | $11.8M | $12.4M | $12M | $27.1M |
| Net debt | $19.3M | $11.5M | $8.59M | -$-8.72M | $26.8M |
| Total equity | $18.4M | $24.5M | $36M | $39.7M | $4.38M |
| Cash and short-term investments | $760K | $340K | $3.85M | $20.8M | $300K |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $65.3M | $54.4M | $53.4M | $50.4M | $56.2M |
| Cost of revenue | $57.4M | $50.1M | $49M | $44.4M | $47.9M |
| Gross profit | $7.9M | $4.31M | $4.35M | $5.96M | $8.33M |
| Research and development expenses | $520K | $530K | $0.00 | $0.00 | $0.00 |
| Selling, general and administrative expenses | $22.6M | $12.1M | $25.6M | $13.2M | $12.4M |
| Other expenses | $1.37M | $7.23M | $610K | $190K | $450K |
| Operating expenses | $24.4M | $19.9M | $26.2M | $13.4M | $12.9M |
| Cost and expenses | $81.8M | $70M | $75.2M | $57.8M | $60.8M |
| Interest income | $400K | $410K | $660K | $240K | $50K |
| Interest expense | $2.62M | $1.01M | $870K | $3.97M | $3.58M |
| Depreciation and amortization | $1.37M | $1.25M | $610K | $190K | $450K |
| Ebitda | -$-15.15M | -$-13.92M | -$-17.06M | -$-8.9M | -$-3.82M |
| Operating income | -$-16.54M | -$-15.54M | -$-21.83M | -$-7.47M | -$-4.53M |
| Total other income/expenses, net | -$-2.6M | -$-640K | $3.29M | -$-5.58M | -$-3.31M |
| Income before tax | -$-19.14M | -$-16.18M | -$-18.54M | -$-13.06M | -$-7.85M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $780K | $110K |
| Net income | -$-19.14M | -$-16.18M | -$-18.54M | -$-13.83M | -$-7.96M |
| Weighted average shares outstanding | $30.3M | $19.2M | $12M | $1.93M | $660K |
| Weighted average diluted shares outstanding | $30.3M | $19.2M | $12M | $1.93M | $660K |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $760K | $340K | $3.85M | $20.8M | $300K |
| Net receivables | $22.6M | $15.9M | $21.7M | $22.8M | $30.1M |
| Inventory | $5.78M | $4.36M | $4.79M | $3.45M | $3.15M |
| Total current assets | $38.4M | $25.5M | $36.6M | $56M | $39.8M |
| Property, plant and equipment, net | $11.8M | $10.4M | $11.6M | $2.93M | $2.93M |
| Goodwill and intangible assets | $7.57M | $7.76M | $7.68M | $710K | $490K |
| Long-term investments | $0.00 | $5.77M | $170K | $0.00 | $0.00 |
| Total non-current assets | $27.1M | $28.9M | $29.4M | $11.7M | $9.6M |
| Total assets | $65.5M | $54.3M | $66M | $68M | $49.4M |
| Accounts payable | $14.6M | $11.2M | $11.9M | $10.3M | $12.1M |
| Short-term debt | $13.7M | $9.76M | $8.54M | $8.31M | $13.6M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $38.3M | $25.8M | $24.3M | $21.8M | $29.9M |
| Long-term debt | $6.23M | $2.06M | $3.89M | $3.72M | $13.6M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $8.78M | $4.02M | $5.65M | $6.63M | $15.1M |
| Capital lease obligations | $600K | $710K | $1.16M | $1.12M | $1.06M |
| Total liabilities | $47.1M | $29.8M | $30M | $28.4M | $45.1M |
| Common stock | $40K | $20K | $20K | $10K | $0.00 |
| Retained earnings | -$-133.17M | -$-114.02M | -$-91.64M | -$-66.23M | -$-34.35M |
| Accumulated other comprehensive income (loss) | $330K | -$-2.13M | -$-420K | -$-1.13M | -$-150K |
| Total equity | $18.4M | $24.5M | $36M | $39.7M | $4.38M |
| Total investments | $50K | $5.8M | $190K | $10K | $10K |
| Total debt | $20M | $11.8M | $12.4M | $12M | $27.1M |
| Net debt | $19.3M | $11.5M | $8.59M | -$-8.72M | $26.8M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-19.14M | -$-16.18M | -$-18.54M | -$-13.83M | -$-7.96M |
| Depreciation and amortization | $1.37M | $1.25M | $610K | $190K | $450K |
| Stock-based compensation | $2.31M | $1.69M | $580K | $20K | $5.9M |
| Change in working capital | -$-780K | $160K | -$-7.9M | -$-8.69M | -$-6.3M |
| Accounts receivable | -$-6.11M | $1.23M | -$-4.03M | -$-7.46M | -$-8.46M |
| Inventory | -$-830K | $150K | -$-890K | -$-490K | -$-90K |
| Accounts payable | $4.47M | $1.05M | $720K | $1.73M | $3.82M |
| Net cash provided by operating activities | -$-8.45M | -$-7.72M | -$-15.64M | -$-14.87M | -$-7.1M |
| Investments in property, plant and equipment | -$-60K | -$-420K | -$-2.98M | -$-70K | -$-580K |
| Acquisitions, net | $0.00 | $0.00 | -$-5.23M | $0.00 | $0.00 |
| Net cash used for investing activities | -$-2.01M | -$-800K | -$-13.76M | -$-20K | -$-830K |
| Common stock issued | $5.42M | $650K | $10M | $35.3M | $250K |
| Common stock repurchased | $0.00 | $0.00 | -$-100K | $0.00 | -$-380K |
| Dividends paid | $0.00 | -$-6.2M | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $14.1M | $5.05M | $12.7M | $35.1M | $7.27M |
| Net change in cash | $3.14M | -$-3.52M | -$-16.92M | $20.5M | -$-340K |
| Cash at end of period | $3.46M | $320K | $3.83M | $20.8M | $290K |
| Operating cash flow | -$-8.45M | -$-7.72M | -$-15.64M | -$-14.87M | -$-7.1M |
| Capital expenditure | -$-60K | -$-420K | -$-9.17M | -$-380K | -$-890K |
| Free cash flow | -$-8.5M | -$-8.14M | -$-24.8M | -$-15.25M | -$-7.99M |
Line items
Line items
Line items
About Cosmos Health Inc.
Cosmos Health Inc. functions as a vertically integrated pharmaceutical firm, providing its own line of branded and generic medicines, nutraceuticals, non-prescription drugs, healthcare and infant products, medical devices, and various other goods. These are distributed via its established channels and an e-commerce marketplace. The company actively seeks, obtains, develops, and commercializes solutions designed to improve patients' well-being and health outcomes. Supporting these operations, it maintains distribution centers in both Greece and the United Kingdom, alongside a dedicated warehousing facility. Its clientele includes wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health Inc. was established in 2009 and has its headquarters in Chicago, Illinois.
- CEO
- Grigorios Siokas
- Employees
- 163
- Beta
- 4.15
Explore
Frequently asked questions
What is the intrinsic value of Cosmos Health Inc. (COSM)?
Cosmos Health Inc. (COSM) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is COSM undervalued?
COSM trades at a price of $2.81 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.